The QualityStocks Daily Thursday, January 20th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(APM) $1.6900 +38.52%

SmallCapRelations(AMST) $1.3100 +15.93%

MarketClub Analysis(AUTO) $3.5400 +11.67%

The QualityStocks Daily Stock List

Dalrada Financial Corporation (DFCO)

QualityStocks, Stockpalooza, Stock Traders Chat and Nebula Stocks reported earlier on Dalrada Financial Corporation (DFCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dalrada Financial Corporation solves real-world problems through producing innovation-focused and technologically-centered solutions on a worldwide level. The Company provides next-generation manufacturing, low carbon clean energy, pharmaceutical and healthcare products and services that provide and increase growth. Incorporated in 1982, Dalrada Financial is based in Henderson, Nevada. The Company also has offices in San Diego, California, and Bangalore, India.

Dalrada Financial lists on the OTC Markets. The Company announced on November 24, 2020 that it has submitted its application for up-listing to the OTCQB.

The Company’s businesses include Dalrada Health, Dalrada Health Products, and Dalrada Precision. Dalrada Health is in the business of solving health problems around the world. It develops products and services that address the unmet needs of consumers due to accessibility, affordability, or availability. Dalrada Health specializes in direct-to-consumer health products with a strong focus on natural, alternative therapies. It has operations in the United States, Malaysia, and India.

Dalrada Precision has a long history of providing design and manufacturing solutions to world-renowned OEMs (Original Equipment Manufacturers). Dalrada Precision helps realize ideas from concept and delivery to after sales service, offering innovative and specific solutions.

Dalrada Health's GlanHealth offers a new alcohol-free sanitizing product. The GlanHealth product line includes Hand Sanitizer Foam, Wipes, and Spray; Advanced Sanitizing Soap; All Purpose Advanced Surface Cleaner; Antimicrobial Wound & Skin Therapy; Mold and Mildew Sanitizing & Prevention; and Laundry Sanitizing & Deodorant.

Dalrada Financial previously announced that The Gynecologist, a global peer reviewed open access scholarly journal, published clinical study research results on Visual Inspection with Acetic Acid (VIA) using Dalrada Health's VIA inspection kits versus Pap smear, a traditional cervical cancer screening method. The study titled "Cervical Cancer Screening with Pap Smear and VIA Using a Novel VIA Kit in a Tertiary Care Hospital in South India" was conducted by Physician Scientist, Dr. Payal Keswarpu, Dalrada Health's Chief Medical Officer, Westchester Knowledge Works in Bangalore, India, and Hethyshi Ranganna from the Department of Obstetrics and Gynecology, Kempegowda Institute of Medical Sciences in Bangalore, India.

Study results include more than 94 percent of the time, VIA and Pap tests results concurred. VIA was highly specific versus Pap smear. Biopsy can be immediately taken in VIA positive cases and detecting and timely treatment of latent infections is an added benefit of VIA kits. Moreover, ready-to-use kits will aid automated imaging analysis in the future.

Dalrada Financial Corporation (DFCO), closed Thursday’s trading session at $0.8595, up 29.151%, on 175,939 volume. The average volume for the last 3 months is 175,939 and the stock's 52-week low/high is $0.10/$0.929.

Aiadvertising Inc. (AIAD)

We reported earlier on Aiadvertising Inc. (AIAD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aiadvertising Inc. (OTC: AIAD) is focused on the provision of digital advertising solutions around the globe.

The firm has its headquarters in San Antonio, Texas and was incorporated in 1998. Prior to its name change in August 2021, the firm was known as CloudCommerce Inc. It serves consumers around the globe.

The company is committed to serving the needs of mid-sized and small businesses by applying artificial intelligence, behavioral science, data science and market research techniques to create custom audiences for targeted digital advertising campaigns.

The enterprise’s products include an audience intelligence solution known as Swarm which conducts an analysis of audience data to help businesses determine how to market themselves, find who to talk to and what they should say. It also offers a reporting and visualization tool known as Honey; a redefined geographic targeting solution dubbed Hive; and an intelligent audience building solution which is known as The Swarm. In addition to this, the enterprise provides a behavior based market research solution known as Buzz. Furthermore, it provides developed and managed infrastructure support services; creative and branding services; digital marketing services; and data analytics for political, manufacturing, logistics, distribution, wholesale and retail, as well as other industries.

The firm recently appointed a new Chief Product and Marketing Officer who has extensive experience in software development and has occupied notable positions in major companies like IBM Sterling Solutions and Cold Stone Creamery. The move may facilitate further development of the firm’s Swarm AI platform, which may have a positive effect on the firm’s growth given that digital advertising is over 50% of all advertising done around the globe.

Aiadvertising Inc. (AIAD), closed Thursday’s trading session at $0.0229, up 21.164%, on 33,461,026 volume. The average volume for the last 3 months is 33.461M and the stock's 52-week low/high is $0.0121/$0.185.

Aptorum Group (APM)

RedChip, QualityStocks, MarketClub Analysis, Red Chip, InvestorPlace, StreetInsider, StockMarketWatch, MarketBeat and BUYINS.NET reported earlier on Aptorum Group (APM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aptorum Group Limited (NASDAQ: APM) (FRA: A1V) is a pharmaceutical firm that is focused on discovering, developing and commercializing therapies for treating various ailments, with a focus on cancers and infectious ailments.

The firm has its headquarters in London, in the United Kingdom and was founded in 2010, on September 13th by Ian Huen. It serves clients across the globe and operates in the healthcare sector, under the biotech and pharma sub-industry.

The company operates through the non-therapeutics and therapeutics segment. The former segment (non-therapeutics) is made up of diagnostics projects which include the sale of natural supplements, AML clinic and a new molecular-based rapid pathogen detection and identification diagnostic tool. On the other hand, the latter segment (therapeutics) is involved in the development of drug molecules and particular technologies for diagnosing and treating human diseases.

The enterprise’s pipeline is made up of various products, among them Claves, Nativus, RPIDD, Acticule and Smart-Act series. It has a few products in preclinical development, including DOI NLS-2, CLS-1, ALS-3, ALS-2, ALS-1 and ALS-4. Additionally, it has developed a product indicated for the treatment of neuroblastoma dubbed SACT-1 for the treatment of neuroblastoma. The enterprise is also centered on pursuing diagnostic projects and therapies in women’s health, metabolic disorders, gastroenterology, neurology and other areas. Furthermore, it has projects that center on natural supplements for women undergoing menopause and those who experience related symptoms as well as in surgical robotics.

The company recently entered into an agreement with Exeltis for the development and commercialization of a preclinical candidate that targets women’s health and gynecological conditions, and in particular endometriosis, which affects about 10% of women within the reproductive age. This product may help address unmet needs, which will be beneficial to the patients in need as well as the firm’s stakeholders.

Aptorum Group (APM), closed Thursday’s trading session at $1.69, up 38.5246%, on 110,563,138 volume. The average volume for the last 3 months is 110.33M and the stock's 52-week low/high is $1.19/$4.94.

Pintec Technology Holdings (PT)

Vantage Wire, SmarTrend Newsletters, InvestorPlace, StockMarketWatch, StreetAuthority Daily, AllPennyStocks, SmallCapVoice, StreetInsider, The Street Report, TheStockAdvisors, TopStockAnalysts, QualityStocks, PennyPro, Investors Alley, TradersPro, Cabot Wealth and Street Insider reported earlier on Pintec Technology Holdings (PT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pintec Technology Holdings Ltd (NASDAQ: PT) is engaged in the provision of information technology services and operates as an independent online technology platform which facilitates financial services in the People’s Republic of China.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in June 2015 by Jun Dong, Xiao Mei Peng, Barry Freeman and Wei Wei. It conducts business worldwide and has a strategic business cooperation with Aspire Holdings Ltd and another with Fullerton Credit, for the development of advanced fintech solutions. The firm aims to leverage technology to level the playing field and advance financial services.

The company’s clients include Minsheng Securities, Industrial Consumer Finance, XWBank, China Telecom’s BestPay unit, VIPSHOP, Ctrip, Qunar and Xiaomi, among others. It launched 2 joint ventures in Singapore, which serve the market in Southeast Asia. One is Pivot, which provides wealth management technologies and was announced in 2017, and the other is Avatec, which offers digital lending technology and was announced in 2018. The company’s robo-advisory engine Polaris and its Dumiao, a digital lending engine, use technologies which include Big Data, Block Chain and Artificial Intelligence.

This firm provides technical consulting, technology promotion, financial application software services, financial data processing and other related services. This is in addition to offering customizable modular fintech solutions to various institutions and their consumers.

The company announced recently that it had entered into an agreement to acquire all of Shenzhen Jishengtai Technology Co. Ltd.’s equity interest. This move will speed up the firm’s plan to transform their business through the expansion of their wealth management services which will in turn grow investor interest in the firm and increase its earnings per share after the transaction is closed.

Pintec Technology Holdings (PT), closed Thursday’s trading session at $0.895, up 15.1866%, on 757,773 volume. The average volume for the last 3 months is 746,227 and the stock's 52-week low/high is $0.40/$2.99.

Alternet Systems (ALYI)

QualityStocks, TJ PennyChase, Tip.us, StocksToBuyNow, Wall Street Corner, Alternet Systems, SeriousTraders, PennyStocks24, Wyatt Investment Research, StockRockandRoll, The Trading Report, PennyStockLocks, Penny Stock 101, Nebula Stocks, BestOtc and Pumps and Dumps reported earlier on Alternet Systems (ALYI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alternet Systems Inc. (OTC: ALYI) is engaged in the provision of marketing intelligence, micro segmentation, data analytics and digital payment services for the telecommunications, financial services, payments and mass consumer goods sectors.

This firm is party to a partnership with iQSTEL Inc., which entails the co-development of 2-way device communication solutions that have been tailored to fit the electric vehicle operating environment. Alternet Systems Inc. operates through its subsidiaries.

The firm, which was founded on June 26, 2000 has its headquarters in Miami Florida and serves consumers in the United States. In addition to this, it also engages in developing and commercializing lithium technologies and provides lithium battery-powered motorbikes and motorcycles.

Apart from offering NFC point of sale solutions to the mobile financial industry, the company also provides financial services software, which includes data analytics tools, payment processing, electronic point of sale modernization, multichannel payment solutions and biometric authentication. The firm also delivers technology solutions to financial organizations that manage payment channels, such as web-based applications, personal computers, tablets, mobile phones and point-of-sale. The enterprise has a large network of industry resources and is guided by executives who’ve specialized in executive and financial management of multi-national organizations, corporate strategy, innovation and entrepreneurial endeavors.

The company recently announced that they’d be expanding their overall electric vehicle ecosystem vision and strategy through a new multitiered deal. This move also includes a new investment into the company, which will substantially contribute to the firm’s balance sheet over the coming period of time, and could be good for the firm’s investors.

Alternet Systems (ALYI), closed Thursday’s trading session at $0.0123, up 19.4175%, on 41,340,709 volume. The average volume for the last 3 months is 41.341M and the stock's 52-week low/high is $0.009/$0.20.

Barfresh Food Group, Inc. (BRFH)

QualityStocks, Greenbackers, Wall Street Resources, OTCJournal, MarketBeat, SmallCapNetwork, Epic Stock Picks, Marketbeat.com, SmallCap Network, Penny Stock Circle, The Wall Street Transcript, The Stock Scout, StockMarketQuote.us, Penny Stock Pros, PennyStockClub, 1-2-3 Stock Alerts, SmallCapVoice, The Best Newsletters, Wyatt Investment Research, StreetAuthority Financial, Stock Alert, RedChip, The Trading Report, Market FN, Lions of Wall Street, InvestmentHouse, Stock Research Newsletter, Trade of the Week, Barchart, AnotherWinningTrade and The Stock Enthusiast reported earlier on Barfresh Food Group, Inc. (BRFH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Barfresh Food Group, Inc. is a manufacturer and distributor of unique, frozen, ready-to-blend beverages. These include smoothies, shakes, and frappes. These products are primarily for restaurant chains and the foodservice industry. Barfresh Food Group and Barfresh Food Group Pty Ltd. in Australia (Barfresh Australia) are under common control. Barfresh Food Group is headquartered in Beverly Hills, California.

Barfresh acquired the exclusive worldwide patent rights to its ready-to-blend beverage packs. This is on top of its presently held patent rights in the United States and Canada. The Company acquired the intellectual property (IP) for its creative “ready to blend” ingredient packs for North America.

Barfresh Food Group has approval to sell its products into all branches of the U.S. Armed Forces. This covers bases around the world that are home to 1.3 million active troops. Barfresh has entered into agreements expanding to a host of military locations.

Barfresh’s proprietary, patented system uses portion-controlled pre-packaged beverage ingredients. These deliver freshly made smoothies that are quick, cost efficient, and without waste.

The innovative system combines all the ingredients of a quality smoothie into an individually pre-portioned pack. The pack contains real fruit pieces, low fat frozen yogurt or sorbet, fruit juice, and ice. These are subsequently blended with water to create a smoothie.

Barfresh Food Group previously announced that it has approvals for 100 locations across numerous branches of the military throughout the U.S.

Barfresh Food Group, Inc. (BRFH), closed Thursday’s trading session at $6.4799, up 17.8164%, on 888,865 volume. The average volume for the last 3 months is 844,309 and the stock's 52-week low/high is $3.1213/$13.38.

Industrial Nanotech Inc. (INTK)

Stock Guru, UndiscoveredEquities, OTCPicks, The Cervelle Group, Industrial Nanotech, PennyTrader Publisher, Stock Stars, TheStockWizards.net, Stocks That Move, MadPennyStocks, PennyInvest, Greenbackers, SmallCapVoice, FeedBlitz, CoolPennyStocks, HotOTC, PennyStockVille, BullRally, QualityStocks, WiseAlerts, StockEgg, StockGuru, StockRich, The Cevelle Group and Pumps and Dumps reported earlier on Industrial Nanotech Inc. (INTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Industrial Nanotech Inc. (OTC: INTK) is focused on the development, manufacture and marketing of industrial grade insulation products using nanotechnology.

The firm has its headquarters in Naples, Florida and was incorporated in 2004 by Stuart Burchill and Laurie Ann Burchill. The firm serves consumers around the globe, with a focus on the United States.

The company takes part in and funds nanoscience research with leading laboratories and scientists globally. It creates unique nanotechnology-based materials for home and industrial use. The company is focused on commercializing new and innovative applications for sustainable nanotechnology.

The enterprise’s products include Nansulate Translucent High Heat and Nansulate Translucent PT, which are corrosion prevention and protective thermal insulation coatings; Nansulate Insulation for solar thermal equipment, solar water heaters and solar panels; an automotive coating known as Nanoboost; lead encapsulation coating for lead abatement dubbed Nansulate LDX Clear; a shield which provides cool color choices for exterior painting projects dubbed Intelligent Shield; roof coating for mold resistant protection and clear energy saving, known as Nansulate Crystal; a protective insulation and mold prevention coating dubbed Home Protect ClearCoat; EPX4 for total asset protection; a mold resistant and insulation coating for food sensitive environments dubbed Nansulate Translucent GP NSF; and a formulation for protecting bees in their hives known as Bee Protect.

The company is focused on expanding its operations in EU countries, having recently received its first order from Nanotech Coatings Ltd. The company is well equipped to meet the needs of most countries which are working to meet the Smart Finance for Smart Buildings initiative, which will be good for its revenue as well as investments into the company.

Industrial Nanotech Inc. (INTK), closed Thursday’s trading session at $0.0216, up 2.8571%, on 9,989,009 volume. The average volume for the last 3 months is 9.989M and the stock's 52-week low/high is $0.0001/$0.031.

Hyzon Motors (HYZN)

MarketClub Analysis, MarketBeat, Schaeffer's and InvestorPlace reported earlier on Hyzon Motors (HYZN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hyzon Motors Inc. (NASDAQ: HYZN) is a hydrogen mobility firm that is focused on the manufacture of hydrogen-powered fuel cell systems and commercial vehicles.

The firm has its headquarters in Honeoye Falls, New York and was incorporated in 2020. Prior to its name change, the firm was known as Decarbonization Plus Acquisition Corporation. It operates as part of other electrical equipment and component manufacturing industry. The firm has five companies in its corporate family and serves consumers in the United States, China, Australia, Singapore and Europe.

The company’s objective is to design, develop and manufacture both integrated and standalone hydrogen fuel cells and systems as well as purpose-designed hydrogen-powered commercial vehicles. It’s focused on accelerating the energy transition through the manufacture and supply of hydrogen fuel cell-powered commercial vehicles. The company’s subsidiaries include Hyzon Zero Carbon Inc.

The enterprise is developing a purpose-built hydrogen-powered truck with a fuel cell optimized chassis dubbed SuperH2Truck. Its commercial vehicle business is focused on the manufacture and supply of medium-duty trucks, heavy duty trucks and 18-meter and 12-meter coach and city buses to commercial vehicle operators. The enterprise serves logistics and shipping companies, mining and port equipment operators and manufacturers, plus retail customers with distribution networks.

The firm is set to grow significantly and occupy a larger market share as government support for hydrogen increases and countries around the globe work to decarbonize their economies in order to meet their net-zero targets. The commercial understanding of the unique suitability of fuel cell electric vehicles for heavy transport is also growing, which will play a key role in decarbonizing commercial mobility.

Hyzon Motors (HYZN), closed Thursday’s trading session at $4.42, off by 1.3393%, on 2,682,872 volume. The average volume for the last 3 months is 2.683M and the stock's 52-week low/high is $4.40/$19.95.

Global Fiber Technologies (GFTX)

QualityStocks and PoliticsAndMyPortfolio reported earlier on Global Fiber Technologies (GFTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Global Fiber Technologies Inc. (OTC: GFTX) is a fiber rejuvenation firm that is engaged in the provision of branded uniforms, apparel and fabrics.

The firm has its headquarters in Somerset, New Jersey and was incorporated in 2004. Prior to its name change in January 2017, the firm was known as EcoTek 360 Inc. It serves consumers around the globe, with a focus on the United States.

The company’s aim is to create foundational change in the authentication, rejuvenation and facilitation areas of the fiber industry, to drive innovation as well as bring cutting edge attributes and value added properties to the apparel, textile and fiber industries. It operates through the Rejuvenated Cardboard and Rejuvenated Uniform segments. The former segment is focused on rejuvenated technologies while the latter segment is involved in the production and marketing of garments and other accessories for the commercial uniform. The company operates through the Fiber-chain LLC, EcoTek 360 and Authentic Heroes Inc. subsidiaries.

The enterprise is focused on ecology and sustainability and provides textile and apparel technology for designing and making sustainable uniforms. Its client base includes the education, hospitality, military, food service, transportation, medical, manufacturing and other commercial uniform industries.

The firm is planning to create a joint venture with Maestro Entertainment, through its Authentic Heroes Inc. subsidiary, which entails turning classic records into collectible NFT bundles. This move will create additional opportunities for both companies while allowing Global Fiber to venture into a new market, which will be good for its investments as well as its growth.

Global Fiber Technologies (GFTX), closed Thursday’s trading session at $0.007, off by 1.4085%, on 27,858,317 volume. The average volume for the last 3 months is 27.858M and the stock's 52-week low/high is $0.0002/$0.0171.

BuzzFeed Inc. (BZFD)

MarketBeat and The Street reported earlier on BuzzFeed Inc. (BZFD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BuzzFeed Inc. (NASDAQ: BZFD) is a tech-powered diversified media firm that is focused on the provision of original reporting, breaking news, entertainment and videos across the social web.

The firm has its headquarters in Rye, New York and was incorporated in 2020, on September 9th. Prior to its name change, the firm was known as 890 5th Avenue Partners Inc. It operates as part of the advertising, public relations and related services industry. The firm has fifteen companies in its corporate family and serves consumers around the globe, with a focus on the United States.

The company’s objective is to provide quality, trusted and brand-safe news and entertainment to millions of individuals around the globe while making content on the internet more creative and inclusive and inspiring its audience to live better lives.

The enterprise’s cross-platform network, BuzzFeed Originals, produces videos, quizzes, lists, articles and original series. It also offers BuzzFeed Media, which is made up of a portfolio of identity-driven lifestyle brands, including Goodfil, As/Is, Nifty and Tasty; BuzzFeed News, which includes investigative and reporting journalism; BuzzFeed Studios, which produces original content across digital, film, cable and broadcast platforms; and BuzzFeed Commerce, which develops social commerce experiences and products, licensing and strategic partnerships.

The company is focused on becoming a hub for creatives to thrive in, having recently appointed a new CEO who brings to the table a wealth of operational experience. This move will help the company unlock its potential for even greater growth, which will be good for investments as well as its revenues.

BuzzFeed Inc. (BZFD), closed Thursday’s trading session at $4.04, off by 2.4155%, on 153,120 volume. The average volume for the last 3 months is 153,099 and the stock's 52-week low/high is $4.0101/$14.77.

Bark Inc. (BARK)

MarketBeat, Daily Trade Alert and CNBC Breaking News reported earlier on Bark Inc. (BARK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bark Inc. (NYSE: BARK) is a dog-centric firm that is engaged in the provision of services, products and content for dogs.

The firm has its headquarters in New York and was incorporated in 2012 by Carly Strife, Henrik Werdelin and Matt M. Meeker. Prior to its name change, the firm was known as The Original Bark Company. It operates as part of the miscellaneous non-durable goods merchants’ wholesalers’ industry. The firm serves consumers around the globe.

The company operates through the Commerce and Direct to Consumer segments. It is devoted to making dogs happy with the best content, services and products. The company’s team employs its data-driven understanding of things that makes every dog special, to create satisfying treats and wellness supplements as well as playstyle-specific toys, and experiences that foster the happiness and health of dogs around the globe.

The enterprise serves dogs via monthly subscription services. It provides monthly themed boxes of treats and toys under the SuperChewer and BarkBox names; health and wellness products under the Bark Bright name; meal plans under the Bark Eats name; and dog leashes, harnesses, collars, bowls and beds under the Bark Home brand. The enterprise also provides custom collections through brick and mortar retail partners and online marketplaces. This is in addition to selling Bark Home products via BarkShop.com.

The firm plans to leverage its scale and brand to grow its footprint in areas like health and food, which may have a positive impact on its growth and help extend its consumer reach. It is focused on capitalizing on opportunities that satisfy its consumers, bring in more revenues and drive its growth.

Bark Inc. (BARK), closed Thursday’s trading session at $3.66, off by 1.8767%, on 2,419,047 volume. The average volume for the last 3 months is 2.413M and the stock's 52-week low/high is $3.37/$13.57.

Bragg Gaming Group, Inc. (BRAG)

RedChip and QualityStocks reported earlier on Bragg Gaming Group, Inc. (BRAG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bragg Gaming Group, Inc. is a next generation gaming group with pioneering technology, leading brands, and world-class management expertise. The Company’s portfolio includes ORYX Gaming, an innovative B2B (Business to Business) gaming technology platform and casino content aggregator and GIVEMESPORT, a foremost sports media outlet with greater than 26M fans, the number one Facebook Sport Publisher. OTCQX-listed, Bragg Gaming Group is headquartered in Toronto, Ontario.

The Company was established in 2018 by way of two initial acquisitions. Bragg Gaming specializes in identifying online gaming opportunities with an emphasis on B2B and B2C (Business to Consumer) gaming companies. Bragg has built business relationships across Asia, Europe, Central America, and North America.

The Oryx acquisition is its initial step on the road to the formation of a new international gaming group. Bragg Gaming’s plan is to follow this with other acquisitions in the gaming sector. This is as it positions the Company as a next generation gaming business. Additionally, Bragg’s GIVEMESPORT, a sports media outlet, has a larger following on Facebook than ESPN and Sky Sports.

With its industry-leading technology, Bragg Gaming provides a turnkey solution. This includes an omni-channel retail, online, and mobile iGaming platform, and also advanced casino content aggregator, sportsbook, lottery, marketing, and operational services. Its content aggregator is renowned for its quick and seamless integration. Bragg’s content aggregator combines casino, slots, live dealer, lottery, virtual sports, and instant-win game content from top tier gaming content providers, along with proprietary content. Moreover, it is completely compliant with major regulated jurisdictions.

Bragg Gaming Group, Inc. (BRAG), closed Thursday’s trading session at $5.4, up 14.4068%, on 45,187 volume. The average volume for the last 3 months is 45,187 and the stock's 52-week low/high is $4.41/$15.7666.

The QualityStocks Company Corner

Growth Capital Acquisition Corp. (NASDAQ: GCAC)

The QualityStocks Daily Newsletter would like to spotlight Growth Capital Acquisition Corp. (NASDAQ: GCAC).

NetworkNewsWire Editorial Coverage: Mainstream fully autonomous vehicles are not an if, they are a when. The bigger question is what it is going to take from a technical end to get self-driving cars and trucks safely maneuvering along every side street and highway. As one can imagine, the 2022 Consumer Electronics Show in Las Vegas this month was once again a hotbed of activity featuring the future of autonomous vehicles. The opening keynote was presented by Mary Barra, chair and CEO of General Motors, detailing the automaker’s vision of GM leading the industry transformation underpinned by connectivity, electrification and autonomy. How the industry reaches that end is the subject of different business models, but it seems a safe bet that it will include a confluence of technologies, including the powers of LiDAR to make autonomous driving as commonplace as power windows and brakes. GM has partnered with the LiDAR experts at Cepton Technologies, which plans to come public early this year via a highly anticipated SPAC merger with Growth Capital Acquisition Corp. (NASDAQ: GCAC) (Profile). Cepton is in the thick of the industry that provides investors exposure to autonomous vehicles through multiple avenues, having engagements with all of the top 10 auto manufacturers. This list includes GM, which has already chosen Cepton’s LiDAR (Light Detection And Ranging) for its Ultra Cruise; Ford Motors, with which Cepton already has a contract for Smart Cities; Toyota Motor Corporation (NYSE: TM), which is one of the biggest shareholders of Cepton’s Tier 1 partner Koito; and forward-looking Stellantis N.V. (NYSE: STLA). Cepton may have the inside track on a few of these engagements, making it a potential excellent play on the evolution of the automobile and the driving experience. In addition, Qualcomm Incorporated (NASDAQ: QCOM) is a part of this evolution, having partnered with GM for its Ultra Cruise and with Cepton on its Smart City Accelerator Program.

Growth Capital Acquisition Corp. (NASDAQ: GCAC), a publicly traded special purpose acquisition company listed on February 2, 2021, with $172.5 million in Trust, and Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance MMT® lidar solutions, on August 5, 2021, announced their entry into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed ‘Cepton Inc.’ and is expected to be listed on the Nasdaq stock exchange under new ticker symbol ‘CPTN’.

The proposed business combination, which has been unanimously approved by the boards of directors of Cepton and Growth Capital, is expected to be completed early in the first quarter of 2022, subject to, among other things, approval by Growth Capital’s stockholders, satisfaction of the conditions stated in the definitive agreement and other customary closing conditions.

Cepton Technologies Inc. is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s proposed merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Growth Capital Acquisition Corp. (NASDAQ: GCAC), closed Thursday’s trading session at $9.94, up 0.201613%, on 510,189 volume. The average volume for the last 3 months is 510,186 and the stock's 52-week low/high is $9.55/$9.99.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
  • The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
  • All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
  • Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension. Lexaria Bioscience (NASDAQ: LEXX) CEO and chair Chris Bunka is the guest on a recent episode of the EDGE podcast. Hosted by entrepreneur and angel investor Brandon C. White, the EDGE is a podcast series focused on providing a playbook for business owners that takes a look at the inner game of building a successful business and giving listeners the edge to become smarter, healthier and richer. Lexaria Bioscience is a global innovator in drug-delivery platforms. During the interview, Bunka shared his background and the journey that led him to Lexaria. He also talked about Lexaria’s business model and the company’s focus on improving the delivery of active pharmaceutical ingredients, vitamins and minerals. In addition, he discussed Lexaria’s ongoing efforts to leverage its innovative drug-delivery platform to improve the effectiveness of orally delivered compounds. “Lexaria Bioscience is a tech company, and we provide really, really interesting solutions to the pharmaceutical industry, as well as nutraceuticals and even delivery of beneficial vitamins and minerals in foods,” said Lexaria Bioscience CEO and chair Chris Bunka in the podcast. “Our technology is all about enabling a much higher fraction and a much smoother delivery of the beneficial substances in the foods you eat and in the drugs you take and, quite frankly, getting them into your bloodstream. With a lot of these compounds and drugs, the vast majority of what you eat or swallow ends up in the toilet, and that’s no good. So we can fix that.” To view the full interview, visit https://ibn.fm/153ow. To view the full press release, visit https://ibn.fm/I4MeO.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday’s trading session at $4.7, up 1.0753%, on 63,063 volume. The average volume for the last 3 months is 62,882 and the stock's 52-week low/high is $3.779/$12.50.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

  • Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS 
  • Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
  • NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
  • Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) - a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. 

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Thursday’s trading session at $4.3, up 2.381%, on 15,616 volume. The average volume for the last 3 months is 15,505 and the stock's 52-week low/high is $4.03/$17.40.

Recent News

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

A new study conducted by researchers from the University of California-Berkeley, the Northeastern University and Boston University has found that the new screening guidelines for lung cancer have significantly grown the eligibility of Black women. The U.S. Preventative Services Taskforce, which is made up of experts in evidence-based and preventative medicine, changed the lung cancer screening guidelines in April 2021 by reducing the required smoking “pack-years” to 20 from 30 and lowering the screening age of eligibility to 50, from 55. Palmer added that the new guidelines would help improve earlier detection, which would enhance survival rates for Black women with lung cancer, especially when many more companies such as AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) come out to advance the cancer diagnostics segment.

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://nnw.fm/L7css). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Thursday’s trading session at $1.13, up 3.6697%, on 221,143 volume. The average volume for the last 3 months is 221,138 and the stock's 52-week low/high is $1.01/$12.09.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

New research carried out by researchers at the Oregon State University and the Oregon Health and Science University has discovered that some hemp compounds may be able to prevent SARS-CoV-2 from entering cells in the human body. SARS-CoV-2 is the virus that causes the coronavirus infection. The study’s findings were reported in the “Journal of Natural Products.” Hemp is a strain of the marijuana plant that has been grown for use in various commercial applications. The plant has very small amounts of THC (tetrahydrocannabinol), which is one of the two primary compounds found in cannabis, the other being CBD. Unlike THC, which is a psychoactive that usually induces a high, CBD (cannabidiol) doesn’t possess psychoactive properties. Studies have shown that CBD can help manage depression, anxiety and even seizures. It is exciting to know that so much more about the therapeutic potential of the cannabis products made by established companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is still being discovered and documented. It could take many more years before this versatile plant is fully understood.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Thursday’s trading session at $0.4097, up 2.425%, on 195,636 volume. The average volume for the last 3 months is 195,636 and the stock's 52-week low/high is $0.289/$1.65.

Recent News

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

  • Over 466 million people current suffer from disabling hearing loss with a further 1.1 billion people at risk of suffering hearing damage
  • Elevated device cost, poor after-sales service, and a lack of access to proper healthcare have led to only 14% of the 48 million American with hearing loss to currently use hearing aid devices
  • InnerScope Hearing Technologies has sought to address this issue with its affordable direct-to-consumer sales model
  • InnerScope CEO, Matthew Moore presented at the Emerging Growth Conference on January 5th, updating shareholders and investors on the company’s latest operational highlights

As of March 2019, the World Health Organization (“WHO”) estimated that disabling hearing loss affected around 466 million people across the globe, out of whom 34 million were children. Moreover, the WHO forecast that up to 1.1 billion people between the ages of 12 to 35 years globally were subject to hearing loss risk, largely due to constant noise exposure (https://ibn.fm/ftcaw). InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has long sought to become a leader in the direct-to-consumer hearing aid market, with the goal in mind to provide affordable hearing to the tens of millions of Americans suffering from hearing loss today.

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

  • First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
  • Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
  • The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
  • Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Thursday’s trading session at $0.01, up 0.502513%, on 11,339,642 volume. The average volume for the last 3 months is 11.34M and the stock's 52-week low/high is $0.0009/$0.098.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FRA: 7CR) is a propriety software-as-a-service (“SaaS”) technology company delivering mobile live dealer technology (VegasLounge(TM)) to online gaming operators globally. The company announced that it has gone live with four new operators, now offering Playgon's Live Dealer games to global clients. This brings Playgon to a total of 30 operators utilizing the company's technology, with an additional five operators in the queue at various stages of onboard testing. “We are very pleased to welcome four new operators into the Playgon family. They are impressed with our technology and are already contributing to player activity on our platform,” said Darcy Krogh, CEO of Playgon Games. “We continue to hear positive reviews from operators seeking new and innovative content, and our mobile Live Dealer solution is a prime example of that as we continue to garner interest in the online gaming community. Momentum continues to grow in player activity on a month over month basis, and we are on track for a record 2022.” To view the full press release, visit https://ibn.fm/anOSo

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.

Games

Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Thursday’s trading session at $0.22, even for the day, on  volume. The average volume for the last 3 months is 4,000 and the stock's 52-week low/high is $0.197/$0.6282.

Recent News

Nowigence Inc.

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc.

  • Personal knowledge management involves creating systems, adding context and making information easy to surface when needed
  • The customizable, user-friendly Pluaris platform assists users with reading and analyzing textual data and so much more
  • Nowigence is focused on simplifying the challenges of learning

The idea of personal knowledge management (“PKM”) systems is gaining traction, with a growing number of individuals and companies recognizing the importance of managing information more efficiently for more successful outcomes. Seeing an opportunity to provide critical support in this quest for knowledge management, Nowigence has created Pluaris(TM), a cloud-based app that automates reading and analysis of textual data so users can learn more in less time while uncovering hidden insights and staying on top of the information they need to know. 

Nowigence Inc. is a fast-growing SaaS (Software-as-a-Service) company that develops and sells a ready-to-use artificial intelligence (AI) platform called Pluaris™ that automates reading and analysis of textual data. Individuals, teams, and enterprises can now quickly distill knowledge buried in narrative-intensive documents instantaneously from various data sources, both public and private.

Pluaris is created for those who want to read more in less time. It is a Personal Knowledge Management (PKM) tool that generates an annotated data feed based on your topics of interest and automatically creates a permanent personal knowledge base from your feed and private uploads. It has human-like capabilities for comprehending textual data. It summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.

By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Nowigence puts the power of data science in the hands of consumers. It helps individuals, teams, and organizations to quickly build expertise on one or multiple topics by generating a trove of critical information.

Nowigence targets two user types that rely heavily on fast and accurate research as primary adopters of the Pluaris platform. The first is knowledge workers of all kinds – anyone whose job is to “think for a living” like marketing professionals, researchers, legal professionals, academics, journalists, editors, scientists, and other professionals. The second are individual users who are life-long learners, hobbyists, and enthusiasts of all stripes.

Rather than spending time reading information to gain knowledge from one source at a time, users of Pluaris can gain knowledge from hundreds or thousands of sources in seconds. Keyword-based search-and-retrieval applications don’t open documents, nor read their content, nor extract key points, conduct cause and effect analysis or answer questions specifically. Pluaris includes all those features and goes one step further, with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also reduces “noise” by extracting only important and relevant information on every topic being monitored or researched. This helps cut down on information overload, a major source of workplace stress.

Pluaris Builds Intelligence

The Problem

In the modern world, virtually everyone needs to consume a tremendous amount of text-based information, in both our personal and professional lives, but doing so is exceptionally challenging because of:

  • Information Overload: For virtually any significant topic of interest, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: Thanks to modern technology, we are constantly bombarded with new inputs (e-mails, instant messages, social media, and more) reducing our attention span, leading all too often to TL;DR (Too Long, Didn’t Read).
  • Highly Imperfect Human Recall: The information that we do find time to read is easily forgotten. Even if we retain some of the key insights, the details are almost certainly lost.

Even when working in teams, we often end up researching the same content as our colleagues, and too much of the information acquired by one individual is lost in translation with the communication process to others.

Pluaris

Nowigence has worked with stalwarts and pioneers in the fields of Machine Learning (ML) and Natural Language Processing (NLP) from its early days. The company was keen to solve the big problem of the information age – too much data exists and cannot be processed manually.

Pluaris is designed to be used by regular people from day one with no need for extensive training. The platform is used across different functions and sectors, adapting to clients’ ever-changing needs. Its state-of-the-art no code editing gives organizations the flexibility to improve and tailor their results without hiring data scientists, and real time information retrieval ensures the client never misses any piece of intelligence.

Pluaris adapts to the unique needs by which individuals absorb knowledge. It doesn’t impose structured or rigid methodology. Real time operation means that Pluaris will deliver outputs instantaneously with a click.

A Nowigence team of experts spent three years training Pluaris to understand the context of every sentence it reads. If Pluaris does make an error in contextual interpretation, the user can correct it, which will instantly give the correction precedence over the ML’s algorithmic outputs. This takes away the biggest criticism against AI/ML platforms, that annotating (labeling) data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

I need to stay on top of the latest news for my industry. Pluaris automatically retrieves and analyzes news on your topics of interest every day, so you can quickly scroll through an annotated news feed on your phone, tablet or laptop, while finishing your morning coffee.

Example: A Pluaris enterprise customer was interested in tracking news and events in the telecom industry. Nowigence was able to quickly create and then fine-tune a list of topics to monitor. In less than a week, they had an annotated news feed covering the telecom industry available to their team.

I have to come up to speed on a new topic as quickly as possible. Upload a few related websites and documents to Pluaris and within minutes you are exploring this new area of interest, scanning the summaries, gaining new insights about this topic, and finding new keywords to broaden your search and deepen your understanding.

Example: A customer who was already using Pluaris for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level.

  • He uploaded a few research reports to Pluaris, read through the summaries, and explored the annotated labels. Based on that analysis, he set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.”
  • From those results, he built an action list of daily habits for diet and fitness and, within a couple months, brought his fasting blood sugar level back down.

I want to be able to access the information I’ve read in the past and synthesize it with my current understanding. As you continue to add more and more information to the system over time, Pluaris never forgets. You are building a knowledge base of the information that is most relevant to you.

Example: A Pluaris user at one of the world’s largest aluminum mining companies was tasked with preparing talking points for her manager for an upcoming investor meeting. Over time using Pluaris, she had built a database of documents, including transcripts, notes, Q&A sessions, speeches, annual reports, and internal documents, some of which were from previous investor meetings. She was able to quickly explore that database through the Pluaris Dashboard and using various filters. She then pulled this information together in a Pluaris Notebook and shared that note directly with her boss.

Market Outlook

Pluaris users include:

  • Knowledge WorkersGartner estimates there are more than 1 billion worldwide as of December 2019.
  • Students in Higher Education: ICEF estimates there are 250 million worldwide as of 2020. This is Nowigence’s initial target group from a market penetration perspective.
  • Personal/Home Use: Statista estimates there are 4.7 billion active internet users worldwide as of January 2021.

Nowigence offers tiered pricing, starting at $10/month/user for individuals, while team and enterprise users, who have access to more features to facilitate collaboration and integrations to other enterprise tools, start at $45/month/user.

As a result, the Total Available Market (TAM) is more than a billion users and over $1 trillion. The Market Opportunity (the Serviceable Obtainable Market or SOM) for Nowigence is $11 billion in the combined PKM and Cognitive Computing space defined by Pluaris.

This market is growing rapidly too. The Cognitive Computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026, growing at a CAGR of 31.6% from 2019 to 2026, according to Allied Market Research.

Nowigence offers differentiated value compared to other Personal Knowledge Management (PKM) tools, which have reached as many as 250 million users (Evernote) and have shown rapid adoption (Roam Research reached 60,000 users and $1 million ARR within 6 weeks of launching paid plans). Unlike Pluaris, these tools do not automatically monitor public or private sources to add to your knowledge base, nor do they provide summaries or extract intelligence. Pluaris differs from search engines as well, in that search engines do not access or store personal knowledge, and they also do not summarize or extract intelligence.

Management Team

Anoop Bhatia is the founder and CEO of Nowigence Inc., where he has worked full-time since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). He has worked for over two decades in various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. He received his Bachelor of Engineering in Chemical Engineering from BITS in India and did his post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt is the Chief Technology Officer at Nowigence. He has more than 20 years of experience building and leading diverse engineering and operations teams, and a strong technical background in machine learning, signal processing, and statistical data analysis, including applications in speech and text, biotechnology, and computer vision. He is a named inventor on 15 issued patents and is experienced in all phases of engineering development and operations. He holds a B.S. degree in Engineering Mechanics from the University of Wisconsin and M.S. and Ph.D. degrees from Stanford University in Aeronautics and Astronautics.

David Evans is the company’s acting CFO & General Counsel. As an attorney and licensed CPA in the state of New York, he has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes being a Managing Director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants and a past president of the Estate Planning Council of Eastern New York. He holds degrees from Hofstra University and State University of New York at Buffalo.


Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

  • SRAX's performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M - $48M.
  • Company's SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance.
  • As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M - $48M, an increase of 46% - 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday’s trading session at $5.06, off by 4.1667%, on 163,916 volume. The average volume for the last 3 months is 157,330 and the stock's 52-week low/high is $2.91/$7.29.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

The 2022 Consumer Electronics Show was every car enthusiast’s dream. Running from Jan. 5­­–8, 2022, the show featured some of the latest technologies different companies had to offer. With electric vehicles (“EVs”) being among the most talked-about technology right now, they featured heavily during the show. Several countries across the world are looking to reduce their carbon emissions, and tackling transportation is the first step; passenger vehicles and light-duty trucks accounted for 29% of total carbon emissions in 2019. By replacing fossil fuel cars with zero-emission electric vehicles, we can significantly cut down on our greenhouse gas emissions. One company, however, took the concept of being green and eco-friendly to the extreme. German automaker Mercedes debuted a new concept electric car that features a completely vegan interior. Dubbed the Vision EQXX, the electric car features a completely animal-free interior made using cactus and mushroom leather, bio-based vegan silk and bamboo. These developments show that as more players sech as Mullen Automotive Inc. (NASDAQ: MULN) gain a bigger market share, the vehicle models that are released will continue to feature lots of improvements to meet the evolving expectations of the clientele.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday’s trading session at $3.69, off by 1.0724%, on 207,278 volume. The average volume for the last 3 months is 205,507 and the stock's 52-week low/high is $3.54/$17.87.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part of the virtual event, the company will provide a corporate presentation followed by an interactive Q&A session. In addition to the moderated portion, investors and attendees will have the opportunity to submit questions live during the event or in advance of the conference via www.VirtualInvestorCo.com. A live video webcast of the presentation will be available on the company’s website, with a webcast replay available two hours following the live presentation and accessible for one year. To view the full press release, visit https://ibn.fm/ks6l8

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday’s trading session at $0.7109, off by 4.8327%, on 296,368 volume. The average volume for the last 3 months is 281,096 and the stock's 52-week low/high is $0.6701/$4.46.

Recent News

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced the launch of its new YouTube series entitled “Medically Speaking,” designed to enhance plant-based education and equip consumers with the necessary knowledge to achieve their plant-based goals. The new series will center around informative conversations with the PlantX medical advisory board on plant-based topics. Beyond providing evidence-based information to clarify potential questions and knowledge gaps in the plant-based space, Medically Speaking also aims to offer creative solutions to overcoming plant-based challenges as approved and discussed by trusted health care professionals. “We have seen a tremendous global shift to plant-based diets in recent years and this trend continues to rise,” said PlantX Founder Sean Dollinger. “As the interest in plant-based diets increases, so does the need and demand for engaging plant-based educational opportunities. Medically Speaking was created as a dynamic and evidence-based educational tool that can explain plant-based myths and misinformation and empower people to overcome barriers to change.” To view the full press release, visit https://ibn.fm/TaUgQ

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

  • An easy-to-use e-commerce shopping experience featuring the following:
    • Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
    • Meal delivery with recipes created by well-known plant-based chefs throughout the world
    • Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
    • Easy to follow plant-based recipes every week
    • Partnerships with restaurants, nutritionists, chefs and brands
    • A community of like-minded individuals
  • State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

  • Shop
  • Find recipes
  • Read blogs
  • Join a community forum
  • Listen to podcasts
  • View cosmetics
  • Research vitamins
  • Purchase plant-based pet foods
  • Read corporate updates
  • Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

  • New meals and programs by renowned chefs
  • Flagship PlantX locations
  • PlantX branded goods
  • United States meal delivery and LIV
  • Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Thursday’s trading session at $0.1203, off by 6.0156%, on 175,938 volume. The average volume for the last 3 months is 175,938 and the stock's 52-week low/high is $0.119/$1.39.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.